Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
A randomized, controlled trial took place across 176 hospitals in the UK compared the outcome of patients who received usual care plus hydroxychloroquine to the outcome of patients on usual care alone for a period of 28 days. Findings did not demonstrate any significant association between hydroxychloroquine and reduction in 28-day mortality. Additionally, hydroxychloroquine was correlated with increased duration until discharge and a greater risk of progressing to invasive mechanical ventilation and death.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19
Hydroxychloroquine as Prophylactic Treatment for COVID-19
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial
Learn After
Methods of Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Results of Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Discussion of Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Limitations of Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.